Igeneon: Staying Close to Home
Executive SummaryIgeneon's latest in-licensing rounds out its cancer immunotherapy pipeline with another compound its founders know well. IGN 301, an epithelial cancer vaccine, is the second of Igeneon's three clinical projects to originate from Novartis. Both were discovered under the guidance of Igeneon's founders, who have a combined 50 years' experience at the Swiss giant.
You may also be interested in...
Recent excitement around exosomes underscores their potential to solve drug delivery challenges that have limited the power and applicability of the biopharma industry’s growing arsenal of therapeutic modalities.